Veea Inc. (NASDAQ: VEEA) saw its shares more than double in premarket trading on Tuesday following the announcement of a non-binding term sheet to combine with privately held NovaGen Group. The proposed transaction, which would create a new entity called NovaGen Health Networks, carries a headline valuation of approximately $750 million. However, that figure is far from a final deal price, and key financial details remain conspicuously absent.
At 8:29 a.m. Eastern on September 15, VEEA shares were trading at $4.03, up 158.3% from Monday's close of $1.56, according to delayed premarket data. The dramatic surge underscores the market's enthusiasm for the potential combination, but it also highlights the speculative nature of the move, as investors have yet to learn what percentage of the combined company current Veea shareholders would own.
What the Term Sheet Actually Establishes
Veea and NovaGen have agreed to negotiate a definitive business-combination agreement “within the coming weeks,” according to a press release issued on September 14. A separate term sheet outlines a $10 million initial investment from GeoNova Capital into the combined entity. Both the merger and the investment remain conditional on the execution of final documents and the satisfaction of customary closing conditions.
The proposed business, NovaGen Health Networks, would combine Veea's edge-computing and cybersecurity platform with NovaGen's personalized-health and regenerative-medicine operations. The first phase of operations is slated to launch at NovaGen clinics and partner hospitals in the fourth quarter of 2026. More advanced diagnostics and therapy programs would follow only as clinical validation and regulatory approvals permit.
The 0 Million Valuation: A Number Without a Basis
Management has stated that the $750 million valuation was derived from internal projections and an independent valuation prepared using those projections. However, the announcement did not disclose the exchange ratio, equity ownership split, consideration to NovaGen holders, fully diluted share count, valuation date, or the underlying assumptions. Without these figures, dividing $750 million by Veea's current share count to arrive at a target price is not a defensible exercise.
“This is a strategic outline, not executable deal economics,” said one analyst who requested anonymity. “Investors are betting on the potential, but they don't have the numbers to validate the price.”
Balance Sheet Raises the Stakes
Veea enters this proposed transaction from a modest financial position. Its June-quarter filing reported just $887,000 in cash, $1.94 million in cash plus restricted cash, and quarterly revenue of $176,000. The company also used $11.1 million in cash for operations during the first half of the year. While these figures predate more recent financing activity, they underscore why the structure and certainty of the proposed $10 million investment are as important as its headline size.
Additionally, Veea executed a one-for-20 reverse stock split effective August 28. A small post-split float can amplify both premarket gains and reversals, meaning the percentage move is not evidence that a $750 million transaction value has been secured.
Bullish Case vs. Reality Check
The bullish case is straightforward: a completed combination could give Veea's technology a clinical distribution channel and a funded health application, leveraging years of development. The counterweight is equally concrete. Until definitive documents specify ownership, dilution, financing conditions, and governance, shareholders hold a strategic outline rather than a binding financial proposal.
Investors will be watching closely for the next disclosures, which could either validate Tuesday's rally or dismantle it. The coming weeks will be critical as Veea and NovaGen work toward a definitive agreement.
